Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 13/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6560096 | 0.99 | CHEK2 (0.54) | CHEK2LTA4HHRH2HRH1AURKB | |
| SCHEMBL6004777 | 0.99 | CHEK2 (0.54) | CHEK2LTA4HHRH2HRH1AURKB | |
| SCHEMBL3866051 | 0.88 | CHEK2 (0.56) | CHEK2LTA4HHRH2HRH1 | |
| Hydrochloric Acid SCHEMBL6561583 | 0.87 | CHEK2 (0.55) | CHEK2LTA4HHRH2HRH1 | |
| SCHEMBL7447377 | 0.86 | LTA4H (0.56) | CHEK2LTA4HHRH2HRH1AURKB | |
| SCHEMBL6053346 | 0.85 | CHEK2 (0.58) | CHEK2LTA4HHRH2HRH1 | |
| SCHEMBL7335065 | 0.85 | LTA4H (0.54) | CHEK2LTA4H | |
| SCHEMBL6560708 | 0.85 | MAPT (0.56) | CHEK2LTA4HHRH2HRH1 | |
| Hydrochloric Acid SCHEMBL7328923 | 0.84 | LTA4H (0.53) | CHEK2LTA4H | |
| SCHEMBL6765314 | 0.83 | CHEK2 (0.52) | CHEK2HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160257-A | Synthetic preparation method of curcumin derivative | 河南省锐达医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-104744428-A | Raloxifene production method | LI LEI | 2015-07-01 | — | — | CN | disclosed |
| EP-1713820-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1709021-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005073204-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073244-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| EP-1551822-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1546139-A1 | DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009578-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009603-A1 | DIHYDRO-DIBENZO[B,E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| WO-2002018364-A2 | PROCESS FOR PREPARING 2-PHENYL-3-AMINOBENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1159268-A1 | N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| WO-2000051983-A1 | N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CHEK2 1773/4885LTA4H 886/4885HRH2 696/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CHEK2 1773/4885LTA4H 886/4885HRH2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.